Recent Findings by G. Bayar and Colleagues in Prostate Cancer Provides New Insights (Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial)
By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting from Istanbul, Turkey, by NewsRx journalists, research stated, "To determine the predictive value of free and bioavailable testosterone levels on the detection of high-grade prostate cancer proven by histopathological examination of transrectal prostate biopsy specimens. A total of 405 patients who underwent transrectal prostate biopsy due to high prostatic specific antigen (PSA) (>2.5 ng/mL) and/or abnormal findings at digital rectal examination were included in this study."
The news correspondents obtained a quote from the research, "Blood free and bioavailable testosterone levels were calculated by the formula recommended by International Society for the Study of the Aging Male (ISSAM). The patients were stratified according to the D'Amico classification based on PSA levels and histological outcomes of prostate biopsies as benign, low, intermediate and high-risk prostate cancer. Patients were also divided into five groups according to the percentage of cancerous cores. Prostate cancer was detected in 160 of 405 (39.5%) patients. Total, free and bioavailable testosterone levels did not differ significantly between the patients with benign or malign histology. However, mean free (6.2 vs. 5.2 ng/dL, p=0.02) and bioavailable (151 vs. 125 ng/dL, p=0.001) testosterone levels were found to be significantly different in men with low-intermediate and high-risk prostate cancer. Moreover, a significant correlation was found between free, and bioavailable testosterone levels and percentage of cores with cancer (p=0.002 for free and p=0.016 for bioavailable testosterone, respectively). This prospective clinical study demonstrates that reduced levels of calculated blood free and bioavailable testosterone levels are associated with an increased risk of high-grade prostate cancer."
According to the news reporters, the research concluded: "Based on these findings blood free and bioavailable testosterone levels may be be thought to be an adjunctive factor in the prediction of high-risk prostate cancer."
For more information on this research see: Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial. Turkish Journal of Urology, 2017;43(3):289-296 (see also Oncology - Prostate Cancer).
Our news journalists report that additional information may be obtained by contacting G. Bayar, Clinic of Urology, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey. Additional authors for this research include H. Sirin, M. Aydin, A. Ozagari, O. Tanriverdi, M. Kadihasanoglu and M. Kendirci.
Keywords for this news article include: Turkey, Eurasia, Istanbul, Oncology, Prostate Cancer, Clinical Research, Prostatic Neoplasms, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC